BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26902691)

  • 1. Metformin may protect nondiabetic breast cancer women from metastasis.
    El-Haggar SM; El-Shitany NA; Mostafa MF; El-Bassiouny NA
    Clin Exp Metastasis; 2016 Apr; 33(4):339-57. PubMed ID: 26902691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial.
    Fairey AS; Courneya KS; Field CJ; Bell GJ; Jones LW; Mackey JR
    Cancer Epidemiol Biomarkers Prev; 2003 Aug; 12(8):721-7. PubMed ID: 12917202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients.
    Papadakis GZ; Mavroudis D; Georgoulias V; Souglakos J; Alegakis AK; Samonis G; Bagci U; Makrigiannakis A; Zoras O
    Growth Horm IGF Res; 2017 Apr; 33():28-34. PubMed ID: 28258988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
    Decensi A; Veronesi U; Miceli R; Johansson H; Mariani L; Camerini T; Di Mauro MG; Cavadini E; De Palo G; Costa A; Perloff M; Malone WF; Formelli F
    Clin Cancer Res; 2003 Oct; 9(13):4722-9. PubMed ID: 14581342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women.
    Serin IS; Tanriverdi F; Yilmaz MO; Ozcelik B; Unluhizarci K
    Gynecol Endocrinol; 2008 Mar; 24(3):117-21. PubMed ID: 18335323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer.
    Johansson H; Baglietto L; Guerrieri-Gonzaga A; Bonanni B; Mariette F; Macis D; Serrano D; Sandri MT; Decensi A
    Breast Cancer Res Treat; 2004 Nov; 88(1):63-73. PubMed ID: 15538047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol.
    Martinez JA; Chalasani P; Thomson CA; Roe D; Altbach M; Galons JP; Stopeck A; Thompson PA; Villa-Guillen DE; Chow HH
    BMC Cancer; 2016 Jul; 16():500. PubMed ID: 27430256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Free insulin-like growth factor-I and breast cancer risk.
    Li BD; Khosravi MJ; Berkel HJ; Diamandi A; Dayton MA; Smith M; Yu H
    Int J Cancer; 2001 Mar; 91(5):736-9. PubMed ID: 11267989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer.
    Helle SI; Geisler J; Anker GB; Leirvaag B; Holly JM; Lønning PE
    Br J Cancer; 2001 Jul; 85(2):147-51. PubMed ID: 11461068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 following chemotherapy for advanced breast cancer.
    Holdaway IM; Mason BH; Lethaby AE; Singh V; Harvey VJ; Thompson PI; Evans BD
    ANZ J Surg; 2003 Nov; 73(11):905-8. PubMed ID: 14616567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins.
    Lawrence JB; Conover CA; Haddad TC; Ingle JN; Reid JM; Ames MM; Suman VJ; Marks RS; Erlichman C; Hartmann LC
    Clin Cancer Res; 1997 Oct; 3(10):1713-20. PubMed ID: 9815555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk.
    Schernhammer ES; Holly JM; Pollak MN; Hankinson SE
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):699-704. PubMed ID: 15767352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer.
    Baglietto L; English DR; Hopper JL; Morris HA; Tilley WD; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):763-8. PubMed ID: 17416768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia.
    Aksoy Y; Aksoy H; Bakan E; Atmaca AF; Akçay F
    Urol Int; 2004; 72(1):62-5. PubMed ID: 14730168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer.
    Fürstenberger G; Senn E; Morant R; Bolliger B; Senn HJ
    Breast; 2006 Feb; 15(1):64-8. PubMed ID: 15998587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-fat diet with omega-3 fatty acids increases plasma insulin-like growth factor concentration in healthy postmenopausal women.
    Young LR; Kurzer MS; Thomas W; Redmon JB; Raatz SK
    Nutr Res; 2013 Jul; 33(7):565-71. PubMed ID: 23827131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective study of insulin-like growth factor-I, IGF-binding proteins-1, -2 and -3 and lung cancer risk in women.
    Lukanova A; Toniolo P; Akhmedkhanov A; Biessy C; Haley NJ; Shore RE; Riboli E; Rinaldi S; Kaaks R
    Int J Cancer; 2001 Jun; 92(6):888-92. PubMed ID: 11351312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular action of insulin-sensitizing agents].
    Kacalska O; Krzyczkowska-Sendrakowska M; Milewicz T; Zabińska-Popiela M; Bereza T; Krzysiek-Maczka G; Krzysiek J
    Endokrynol Pol; 2005; 56(3):308-13. PubMed ID: 16350724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer.
    Eng-Wong J; Hursting SD; Venzon D; Perkins SN; Zujewski JA
    Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1468-73. PubMed ID: 14693739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of insulin-like growth factor binding protein-3 in benign and malignant breast disease.
    Holdaway IM; Mason BH; Lethaby AE; Singh V; Harman JE; MacCormick M; Civil ID
    Aust N Z J Surg; 1999 Jul; 69(7):495-500. PubMed ID: 10442920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.